Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial
出版年份 2021 全文链接
标题
Circulating androgen receptor gene amplification and resistance to 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-08-01
DOI
10.1038/s41416-021-01508-5
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients
- (2020) Giovanni Paganelli et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- TheraP: A randomised phase II trial of 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).
- (2020) Michael S Hofman et al. JOURNAL OF CLINICAL ONCOLOGY
- PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer
- (2019) Elena Castro et al. JOURNAL OF CLINICAL ONCOLOGY
- 177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer
- (2019) Finn Edler von Eyben et al. Oncotarget
- Clinical and molecular analysis of patients treated with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy.
- (2019) Vincenza Conteduca et al. JOURNAL OF CLINICAL ONCOLOGY
- Plasma AR status and cabazitaxel in heavily treated metastatic castration-resistant prostate cancer
- (2019) Vincenza Conteduca et al. EUROPEAN JOURNAL OF CANCER
- Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
- (2019) Alec Paschalis et al. EUROPEAN UROLOGY
- Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
- (2019) Ronald de Wit et al. NEW ENGLAND JOURNAL OF MEDICINE
- Advances in targeted alpha therapy for prostate cancer
- (2019) G De Vincentis et al. ANNALS OF ONCOLOGY
- Genomics of lethal prostate cancer at diagnosis and castration resistance
- (2019) Joaquin Mateo et al. JOURNAL OF CLINICAL INVESTIGATION
- Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: a mechanistic perspective for FDG imaging of PSMA-suppressed tumors
- (2019) Martin K. Bakht et al. JOURNAL OF NUCLEAR MEDICINE
- Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
- (2018) David A. Quigley et al. CELL
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis
- (2018) Sara Bravaccini et al. Scientific Reports
- Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
- (2018) Vincenza Conteduca et al. EUROPEAN UROLOGY
- Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617
- (2017) Hojjat Ahmadzadehfar et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
- (2016) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
- (2016) Kambiz Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013
- (2016) H. R. Kulkarni et al. JOURNAL OF NUCLEAR MEDICINE
- Prostate cancer
- (2016) Gerhardt Attard et al. LANCET
- Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
- (2016) Akash Kumar et al. NATURE MEDICINE
- Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone
- (2015) S Salvi et al. BRITISH JOURNAL OF CANCER
- 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies
- (2015) M. Weineisen et al. JOURNAL OF NUCLEAR MEDICINE
- Plasma AR and abiraterone-resistant prostate cancer
- (2015) Alessandro Romanel et al. Science Translational Medicine
- A Hormone-DNA Repair Circuit Governs the Response to Genotoxic Insult
- (2013) J. F. Goodwin et al. Cancer Discovery
- Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
- (2013) W. R. Polkinghorn et al. Cancer Discovery
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now